BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Owji H, Negahdaripour M, Hajighahramani N. Immunotherapeutic approaches to curtail COVID-19. Int Immunopharmacol 2020;88:106924. [PMID: 32877828 DOI: 10.1016/j.intimp.2020.106924] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Eliseeva DD, Vasiliev AV, Abramova AA, Kochergin IA, Zakharova MN. [Monoclonal antibody therapies for rapidly progressive and highly active multiple sclerosis in the era of the COVID-19 pandemic]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:31-6. [PMID: 34387443 DOI: 10.17116/jnevro202112107231] [Reference Citation Analysis]
2 Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S, Fazlinejad R, Mohammadi-Samani S, Firouzabadi N, Hosseini M, Farjadian F. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiol 2021;16:1415-51. [PMID: 34812049 DOI: 10.2217/fmb-2021-0116] [Reference Citation Analysis]
3 Bagheri A, Moezzi SMI, Mosaddeghi P, Nadimi Parashkouhi S, Fazel Hoseini SM, Badakhshan F, Negahdaripour M. Interferon-inducer antivirals: Potential candidates to combat COVID-19. Int Immunopharmacol 2021;91:107245. [PMID: 33348292 DOI: 10.1016/j.intimp.2020.107245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
4 Chatterjee S, Mishra S, Chowdhury KD, Ghosh CK, Saha KD. Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view. Life Sci 2021;278:119580. [PMID: 33991549 DOI: 10.1016/j.lfs.2021.119580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Machhi J, Shahjin F, Das S, Patel M, Abdelmoaty MM, Cohen JD, Singh PA, Baldi A, Bajwa N, Kumar R, Vora LK, Patel TA, Oleynikov MD, Soni D, Yeapuri P, Mukadam I, Chakraborty R, Saksena CG, Herskovitz J, Hasan M, Oupicky D, Das S, Donnelly RF, Hettie KS, Chang L, Gendelman HE, Kevadiya BD. Nanocarrier vaccines for SARS-CoV-2. Adv Drug Deliv Rev 2021;171:215-39. [PMID: 33428995 DOI: 10.1016/j.addr.2021.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
6 Torrente-López A, Hermosilla J, Navas N, Cuadros-Rodríguez L, Cabeza J, Salmerón-García A. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines (Basel) 2021;9:557. [PMID: 34073559 DOI: 10.3390/vaccines9060557] [Reference Citation Analysis]
7 Safarchi A, Fatima S, Ayati Z, Vafaee F. An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. Cell Biosci 2021;11:164. [PMID: 34420513 DOI: 10.1186/s13578-021-00674-6] [Reference Citation Analysis]
8 Chaudhary JK, Yadav R, Chaudhary PK, Maurya A, Kant N, Rugaie OA, Haokip HR, Yadav D, Roshan R, Prasad R, Chatrath A, Singh D, Jain N, Dhamija P. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Cells 2021;10:2949. [PMID: 34831172 DOI: 10.3390/cells10112949] [Reference Citation Analysis]
9 Silva TF, Tomiotto-Pellissier F, Sanfelice RA, Gonçalves MD, da Silva Bortoleti BT, Detoni MB, Rodrigues ACJ, Carloto ACM, Concato VM, Siqueira EDS, Costa IN, Pavanelli WR, Conchon-Costa I, Miranda-Sapla MM. A 21st Century Evil: Immunopathology and New Therapies of COVID-19. Front Immunol 2020;11:562264. [PMID: 33193331 DOI: 10.3389/fimmu.2020.562264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Negahdaripour M. COVID-19 Vaccine Global Access Is an Urgency. Iran J Med Sci 2021;46:79-80. [PMID: 33753951 DOI: 10.30476/ijms.2021.47336] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Negahdaripour M. Post-COVID-19 Hyperglycemia: A Concern in Selection of Therapeutic Regimens. Iran J Med Sci 2021;46:235-6. [PMID: 34305235 DOI: 10.30476/ijms.2021.47666] [Reference Citation Analysis]
12 Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI, Patel SK, Pathak M, Malik YS, Dhama K, Singh KP, Bonilla-Aldana DK, Haque S, Martinez-Pulgarin DF, Rodriguez-Morales AJ, Leblebicioglu H. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob 2020;19:40. [PMID: 32878641 DOI: 10.1186/s12941-020-00384-w] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
13 Payandeh Z, Mohammadkhani N, Nabi Afjadi M, Khalili S, Rajabibazl M, Houjaghani Z, Dadkhah M. The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. Expert Rev Anti Infect Ther 2021;19:899-910. [PMID: 33307883 DOI: 10.1080/14787210.2020.1863144] [Reference Citation Analysis]
14 Özkan Oktay E, Tuncay S, Kaman T, Karasakal ÖF, Özcan ÖÖ, Soylamiş T, Karahan M, Konuk M. An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. Turk J Biol 2021;45:342-57. [PMID: 34803439 DOI: 10.3906/biy-2106-23] [Reference Citation Analysis]
15 Bayat M, Asemani Y, Mohammadi MR, Sanaei M, Namvarpour M, Eftekhari R. An overview of some potential immunotherapeutic options against COVID-19. Int Immunopharmacol 2021;95:107516. [PMID: 33765610 DOI: 10.1016/j.intimp.2021.107516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rahbar MR, Jahangiri A, Khalili S, Zarei M, Mehrabani-Zeinabad K, Khalesi B, Pourzardosht N, Hessami A, Nezafat N, Sadraei S, Negahdaripour M. Hotspots for mutations in the SARS-CoV-2 spike glycoprotein: a correspondence analysis. Sci Rep 2021;11:23622. [PMID: 34880279 DOI: 10.1038/s41598-021-01655-y] [Reference Citation Analysis]
17 Möhn N, Konen FF, Pul R, Kleinschnitz C, Prüss H, Witte T, Stangel M, Skripuletz T. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. J Clin Med 2020;9:E4067. [PMID: 33339436 DOI: 10.3390/jcm9124067] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
18 Vakili B, Bagheri A, Negahdaripour M. Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations. Biologia (Bratisl) 2021;:1-12. [PMID: 34421121 DOI: 10.1007/s11756-021-00866-y] [Reference Citation Analysis]
19 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
20 Iqbal Yatoo M, Hamid Z, Rather I, Nazir QUA, Bhat RA, Ul Haq A, Magray SN, Haq Z, Sah R, Tiwari R, Natesan S, Bilal M, Harapan H, Dhama K. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. Hum Vaccin Immunother 2021;17:1897-909. [PMID: 33577374 DOI: 10.1080/21645515.2020.1871295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, Johnston TP, Sahebkar A. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19:345-357. [PMID: 32921216 DOI: 10.1080/14787210.2020.1822737] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
22 Negahdaripour M, Rahbar MR, Mosalanejad Z, Gholami A, Tsantili Kakoulidou A. Theta-Defensins to Counter COVID-19 as Furin Inhibitors: In Silico Efficiency Prediction and Novel Compound Design. Computational and Mathematical Methods in Medicine 2022;2022:1-15. [DOI: 10.1155/2022/9735626] [Reference Citation Analysis]
23 Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javad-Mousavi SA, Khodashahi R, Darban M, Kalantari S, Abdollahi N, Salehi MR, Rezaei Hosseinabadi A, Khorvash F, Valizadeh M, Dastan F, Yousefian S, Hosseini H, Anjidani N, Tabarsi P. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. Int Immunopharmacol 2020;89:107102. [PMID: 33075713 DOI: 10.1016/j.intimp.2020.107102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
24 Sadeghian I, Heidari R, Sadeghian S, Raee MJ, Negahdaripour M. Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines. Eur J Pharm Sci 2021;169:106094. [PMID: 34896590 DOI: 10.1016/j.ejps.2021.106094] [Reference Citation Analysis]
25 Rommasi F, Nasiri MJ, Mirsaeidi M. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. Mol Cell Biochem 2022. [PMID: 35013850 DOI: 10.1007/s11010-021-04325-9] [Reference Citation Analysis]
26 Asdaq SMB, Rabbani SI, Alkahtani M, Aldohyan MM, Alabdulsalam AM, Alshammari MS, Alajlan SA, Binrokan A, Mohzari Y, Alrashed A, Alshammari MK, Imran M, Nayeem N. A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19. Int J Mol Sci 2021;22:11953. [PMID: 34769383 DOI: 10.3390/ijms222111953] [Reference Citation Analysis]
27 Mosaddeghi P, Shahabinezhad F, Dorvash M, Goodarzi M, Negahdaripour M. Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19. Hum Vaccin Immunother 2021;17:1650-61. [PMID: 33185497 DOI: 10.1080/21645515.2020.1833577] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Paula HSC, Santiago SB, Araújo LA, Pedroso CF, Marinho TA, Gonçalves IAJ, Santos TAP, Pinheiro RS, Oliveira GA, Batista KA. An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic. Braz J Med Biol Res 2021;55:e11631. [PMID: 34909910 DOI: 10.1590/1414-431X2021e11631] [Reference Citation Analysis]
29 Khan L, Khaliq NU, Ullah A, Rafiq N, Ullah M. COVID-19 pandemic: Mechanistic approaches and gender vulnerabilities. Saudi Pharm J 2020;28:1874-6. [PMID: 33250638 DOI: 10.1016/j.jsps.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]